MetaVia (NASDAQ:MTVA) Upgraded at Wall Street Zen

MetaVia (NASDAQ:MTVA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other analysts also recently commented on MTVA. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. HC Wainwright cut their price target on MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MetaVia has a consensus rating of “Hold” and an average price target of $26.50.

MetaVia Price Performance

Shares of NASDAQ:MTVA opened at $1.22 on Friday. The company has a market capitalization of $2.68 million, a P/E ratio of -0.15 and a beta of 0.33. MetaVia has a 1-year low of $1.21 and a 1-year high of $23.10. The firm’s 50 day simple moving average is $1.81 and its two-hundred day simple moving average is $6.80.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC acquired a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is owned by institutional investors and hedge funds.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.